"Beginning of study. Testing hypotheses that certain groups (of presumably sicker) patients at the start of the trial will benefit more from the drug."

Thanks Jupiter. I was worried that the LDL-C stratification was due to patient compliance of taking study drugs, including statins that control LDL-C. So the comment that BKC shared earlier "Please also note that the question of compliance was raised when the discussant at AHA mentioned the better performance of Apabetalone in the low LDL population relative to the high LDL population" seems to be addressed by this clarification. It was pre-existing baseline LDL-C changes and not during study LDL-C changes that separated the two subgroups.

BDAZ